MX2017006799A - Formulaciones de complejo de metal. - Google Patents

Formulaciones de complejo de metal.

Info

Publication number
MX2017006799A
MX2017006799A MX2017006799A MX2017006799A MX2017006799A MX 2017006799 A MX2017006799 A MX 2017006799A MX 2017006799 A MX2017006799 A MX 2017006799A MX 2017006799 A MX2017006799 A MX 2017006799A MX 2017006799 A MX2017006799 A MX 2017006799A
Authority
MX
Mexico
Prior art keywords
chelator
excess
preparation
metal complex
lanthanide metal
Prior art date
Application number
MX2017006799A
Other languages
English (en)
Inventor
Richard Meijer Andreas
Jacob THANING Mikkel
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of MX2017006799A publication Critical patent/MX2017006799A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La presente invención se refiere a un método de preparación de formulaciones de complejos de metal de lantánido de quelantes macrocíclicos, las cuales comprenden un pequeño exceso de quelante libre. El método usa un quelante depurador unido a fase sólida para remover exceso de iones de metal de lantánido, antes de la adición de un quelante de exceso definido. También se proporciona un método para preparación de agentes de contraste de MRI, junto con sales de meglumina de quelante unido a fase sólida útiles en los métodos. (ver Grafica).
MX2017006799A 2014-11-28 2015-11-27 Formulaciones de complejo de metal. MX2017006799A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1421161.9A GB201421161D0 (en) 2014-11-28 2014-11-28 Metal complex formulations
PCT/EP2015/077958 WO2016083597A1 (en) 2014-11-28 2015-11-27 Metal complex formulations

Publications (1)

Publication Number Publication Date
MX2017006799A true MX2017006799A (es) 2017-09-08

Family

ID=52349616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006799A MX2017006799A (es) 2014-11-28 2015-11-27 Formulaciones de complejo de metal.

Country Status (12)

Country Link
US (1) US11186553B2 (es)
EP (1) EP3223862A1 (es)
JP (1) JP6709216B2 (es)
KR (1) KR102456908B1 (es)
CN (1) CN106999614A (es)
AU (1) AU2015352418B2 (es)
BR (1) BR112017010867B1 (es)
CA (1) CA2967873C (es)
GB (1) GB201421161D0 (es)
MX (1) MX2017006799A (es)
RU (1) RU2710360C2 (es)
WO (1) WO2016083597A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421161D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2019020662A1 (de) * 2017-07-27 2019-01-31 Sanochemia Pharmazeutika Ag Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen
AT521001B1 (de) * 2018-02-23 2020-10-15 Sanochemia Pharmazeutika Ag Herstellungsverfahren für ein Kontrastmittel
WO2019240884A2 (en) * 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
CN108940221A (zh) * 2018-07-27 2018-12-07 福建省微生物研究所 壳聚糖磁性吸附剂除去钆塞酸二钠注射液中游离钆的方法
CN110286168B (zh) * 2019-07-03 2023-03-03 浙江普利药业有限公司 显影剂中多氨基多羧基化合物的测定方法
GB201919073D0 (en) * 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
CN113801071B (zh) * 2021-09-14 2023-04-07 安徽普利药业有限公司 一种钆特酸葡甲胺的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE152623T1 (de) * 1986-12-17 1997-05-15 Glaxo Group Ltd Verwendung von heterozyklischen derivaten zur herstellung von arzneimitteln
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2008144728A1 (en) 2007-05-21 2008-11-27 Bracco Imaging S.P.A. Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications
FR2921271A1 (fr) * 2007-09-20 2009-03-27 Guerbet Sa Formulation d'agents de contraste pour l'irm contenant une polybase organique
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2945448B1 (fr) * 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
EP2338874A1 (en) 2009-12-16 2011-06-29 Bracco Imaging S.p.A Process for the preparation of chelated compounds
GB201421161D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations

Also Published As

Publication number Publication date
CA2967873C (en) 2023-04-04
RU2017116217A3 (es) 2019-06-04
JP6709216B2 (ja) 2020-06-10
RU2017116217A (ru) 2018-12-28
US20170266304A1 (en) 2017-09-21
BR112017010867B1 (pt) 2024-01-02
BR112017010867A2 (pt) 2018-01-09
JP2017538685A (ja) 2017-12-28
CA2967873A1 (en) 2016-06-02
WO2016083597A1 (en) 2016-06-02
AU2015352418A1 (en) 2017-05-18
CN106999614A (zh) 2017-08-01
KR102456908B1 (ko) 2022-10-21
RU2710360C2 (ru) 2019-12-26
US11186553B2 (en) 2021-11-30
EP3223862A1 (en) 2017-10-04
KR20170086048A (ko) 2017-07-25
GB201421161D0 (en) 2015-01-14
AU2015352418B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2017006799A (es) Formulaciones de complejo de metal.
PH12017502205A1 (en) New gadolinium chelate compounds for use in magnetic resonance imaging
PH12015502615A1 (en) Chemical compounds
MX2017014799A (es) Forma cristalina novedosa de mesilato de lenvatinib y procedimiento de preparacion de la misma.
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
IL259836B (en) Dimeric macrocyclic cations, complexes containing them and their uses as contrast agents
IL259901B (en) Functionalized macrocycle chelators, complexes containing same and uses thereof as contrast agents
EP3216782A4 (en) Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof
EA201691363A1 (ru) Стабилизированные силикатные композиции и их применение в качестве антиперспирантных композиций
MX2017006800A (es) Formulaciones de complejo de lantanido.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
PH12017500120A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX2017000306A (es) Metodos para tratar hipotension.
SG11201605003WA (en) Use of non-oxidizing strong acids for the removal of ion-implanted resist
EA201591678A1 (ru) Антиперспирантные композиции
SG11201705595UA (en) Method and kit for dosing iron ions in lubricating compositions
IN2014MN01733A (es)
GB201421661D0 (en) Method for determining the concentration of iron ions in hydrocarbon compositions
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
DK3250213T3 (en) Compositions containing arsenic for use in methods of treatment
EP3132797A4 (en) Use of composition containing iron (ii) amino acid chelate in preparation of drug for ameliorating diabetes
MX2016002198A (es) Proceso para la preparación de un compuesto.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy